Trial · NCT05948891
Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study
NCT05948891, Unknown, Chiesi SAS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study. Trials, record NCT05948891. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05948891
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study
- NCT number
- NCT05948891
- Status
- Unknown
- Enrollment
- 500 participants, estimated
- Lead sponsor
- Chiesi SAS
- Conditions
- COPD
- Interventions
- Beclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)
- First posted
- 2023-07-17
- Last updated
- 2024-03-13
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of quality of life through CAT (COPD assessement tool) over 6 month period | Month 6 | To assess change in QoL using the CAT scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Primary endpoint is the proportion of patients achieving a ≥2-point reduction in CAT total score (MCID) at M6 compared to baseline. |
| Secondary | Mean change Quality of life through VQ11 questionnaire | Month 0, Month 3 and Month 6 | To assess change in QoL using the VQ11 scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is mean VQ11 total score and sub scores described at baseline, M3 and M6 |
| Secondary | Proportion of patients achieving a ≥2-point reduction in VQ11 total score | Month 0, Month 3 and Month 6 | To assess change in QoL using the VQ11 scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is the proportion of patients achieving a ≥2-point reduction in VQ11 total score (MCID) at M3 and M6 compared to baseline. |
| Secondary | Mean change in Dyspnoea throught "Dyspnea-12 questionnaire" | Month 0, Month 3 and Month 6 | To assess changes in dyspnoea using the Dyspnea-12 over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is D-12 total score and sub scores described at baseline, M3 and M6 |
| Secondary | Proportion of patients achieving a 3-point reduction in "Dyspnea-12" total score | Month 0, Month 3 and Month 6 | To assess changes in dyspnoea using the Dyspnea-12 over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is the proportion of patients achieving a 3-point reduction in D-12 total score (MCID) at M3 and M6 compared to baseline. |
| Secondary | Rate of moderate and severe exacerbations at M0, M3 and M6 through eCRF | Month 0, Month 3 and Month 6 | To describe the occurrence of moderate to severe exacerbations over a 6- month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device Endpoint is the proportion of patients with at least a moderate or severe exacerbation (overall and in each category), at baseline (in the previous 12 months), M3 and M6 |
| Secondary | Proportion of patients achieving an increase in physical activity throught the a connected device | Month 0, Month 3 and Month 6 | To assess changes in physical activity using a connected watch over a 6-month • Endpoint is the proportion of patients achieving an increase in physical activity (≥ 10%-increase in the mean daily number of step) at M3 and M6 compared to baseline. Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing watch over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device |
| Secondary | Mean daily number of steps throught the a connected device | Month 0, Month 3 and Month 6 | To assess changes in physical activity using a connected watch over a 6-month • Endpoints are the mean daily number of steps and the mean of number of steps during 7 days at M0, M3 and M6 Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing watch over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device |
| Secondary | Sleep quality throught the Pittsburgh questionnaire | Month 0, Month 3 and Month 6 | • Endpoints are the Pittsburgh questionnaire at M0, M3 and M6 Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing. |
| Secondary | Sleep quality throught the a connected device | Month 0, Month 3 and Month 6 | To assess changes in sleep quality using a connected device • Endpoints are the mean daily sleep time, the mean of sleep time and the mean daily number of awakenings during 7 days at M0, M3 and M6 Baseline sleep quality (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05948891
GET https://conductscience.org/api/trials/v1/NCT05948891/registered